Progress of the COVID-19 Vaccine Effort: Viruses, Vaccines

Total Page:16

File Type:pdf, Size:1020Kb

Progress of the COVID-19 Vaccine Effort: Viruses, Vaccines PROGRESS the first wave of efficacy data and the first vaccine approvals were not the end of the Progress of the COVID-19 vaccine clinical trial phase for COVID-19 vaccines. Ongoing vaccine trials test the efficacy of effort: viruses, vaccines and variants new vaccines in the face of an evolving virus; furthermore, they increase options versus efficacy, effectiveness and for globally dispersed manufacturing of sufficient vaccine doses for global use and strengthen the data for novel vaccine escape platforms that could be of use in future pandemics. As this is a rapidly moving space, John S. Tregoning , Katie E. Flight, Sophie L. Higham, Ziyin Wang the best way to stay abreast of the vaccine and Benjamin F. Pierce trials is through live documents, such as the COVID-19 vaccine tracker from the London Abstract | Where 2020 saw the development and testing of vaccines against severe School of Hygiene and Tropical Medicine. acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented Within this larger list of ongoing pace, the first half of 2021 has seen vaccine rollout in many countries. In this studies, a smaller number of vaccines are Progress article, we provide a snapshot of ongoing vaccine efficacy studies, as well in phase III clinical trials that are yet to as real-world data on vaccine effectiveness and the impact of virus variants of release data: Inovio (DNA, ClinicalTrials. gov identifier NCT04336410), AnGes concern. Where they have been deployed in a high proportion of the adult (DNA, NCT04655625), ReiThera (gorilla population, the currently approved vaccines have been extremely effective in adenovirus, NCT04791423), the Chinese preventing COVID-19, particularly severe disease. Nonetheless, there are Academy of Medical Sciences (inactivated still significant challenges in ensuring equitable vaccine access around the globe virus, NCT04412538), the Research and lessons that can be learned for controlling this pandemic and for the Institute for Biological Safety Problems, Kazakhstan (QazCovid; inactivated virus, next pandemic. NCT04691908), Shifa (inactivated virus, NCT04526990), the Center for Genetic Fifteen months on from the administration and while transmission levels remain high, Engineering and Biotechnology, Cuba of the first experimental COVID-19 vaccine there is an increased likelihood of vaccine (CIGB-66; peptide, RPCEC00000345), doses to humans in March 2020, there is escape variants evolving. In this Progress Clover (peptide, NCT04672395), COVAXX now a global race against the causative article, we cover recent developments (peptide, NCT04545749), the Finlay virus severe acute respiratory syndrome in COVID-19 vaccines since the start of Institute, Cuba (peptide, RPCEC00000332), coronavirus 2 (SARS-CoV-2) to deploy their deployment in late 2020/early 2021, Sanofi–GlaxoSmithKline (adjuvanted vaccines to control the pandemic1, with including real-world data on vaccine protein, NCT04904549), VECTOR differing levels of vaccine rollout in different effectiveness and the impact of viral variants. (peptide, NCT04780035) and Medicago countries (Our World in Data). Despite (plant-derived virus-like particle, authorization having been granted for The current vaccine landscape NCT04636697). We anticipate that some multiple vaccines, as the ongoing global Data from several phase III vaccine efficacy of the candidate vaccines currently in outbreaks demonstrate, the pandemic is trials were reported at the end of 2020, phase III trials will become available for far from over. Vaccination, in combination leading to the approval and rollout of these wider use in quarters 3 and 4 of 2021, which with non-pharmaceutical interventions, is vaccines. The following organizations have will be important in stemming further waves the best way to control the pandemic. In this reported efficacy data for their vaccines as of the pandemic and increasing vaccination regard, we are fortunate that there is now summarized in Table 1: Pfizer–BioNTech2, rates in lower-income countries. a formidable toolkit of potential vaccines Moderna3, AstraZeneca–University of However, it should also be noted available: of the 322 candidate vaccines that Oxford4, Johnson & Johnson5, Gamaleya6, that some fairly high-profile vaccine have been proposed so far (July 2021), 99 are Sinovac Biotech7, Sinopharm7, Novavax8 programmes may not enter phase III in clinical testing, 25 have reached phase III and Bharat Biotech9. As of 14 June 2021, efficacy studies. In collaboration with efficacy studies and 18 have received some each of these vaccines, except for the IAVI, Merck developed the viral-vectored form of approval for use. However, achieving Novavax vaccine, had been approved for COVID-19 vaccine V590 (REF.10). Merck global vaccine coverage remains a major rollout to adults and, in some cases, to also acquired a second COVID-19 vaccine hurdle; this is not just a matter of equity but adolescents through a range of approval through the buyout of Themis, the is also an important part of the process to processes depending on the region and company responsible for producing the control the virus. SARS-CoV-2 continues regulatory agency. This situation remains V591 (live viral vector) vaccine. However, to evolve under immune selective pressure, fluid, and importantly, the publication of the development of both V590 and V591 626 | OCTOBER 2021 | VOLUME 21 www.nature.com/nri 0123456789();: PROGRESS Table 1 | Reported COVID-19 vaccine efficacy data from phase III trials Vaccine Platform Clinical Total Efficacy End point Eligibility Duration of Circulating Results by manufacturer trial trial measure follow up for genotypes at severity (vaccine name)a regime size phase III trial location and time of trial Pfizer–BioNTech mRNA 2 doses 43,548 95% Symptomatic >16 years old Up to 24 B.1.351, P.1, 100% (BNT162b2)2 (21 days COVID-19 months after B.1.427/B.1.419, effective in apart) and positive second dose P.2 and B.1.526 preventing RT–PCR test (NCT04368728) CDC-defined result severe dis- ease; 95.3% effective in preventing FDA-defined severe disease Moderna mRNA 2 doses 30,420 94% Symptomatic ≥18 years old Up to B.1.427/B.1.429 100% efficacy (mRNA-1273)3 (28 days COVID-19 (12 years old 24 months after and B.1.526 against severe apart) and positive to younger second dose disease RT–PCR test than 18 years (NCT04470427) result (NCT04649151) and 6 months old to younger than 12 years (NCT04796896)) AstraZeneca– Viral 2 doses 17 ,178 55% Symptomatic ≥18 years 24 months B.1.1.7 , 100% efficacy University of vector (<6 weeks COVID-19 old (WHO); after first dose B.1.351, P.1, against Oxford (AZD1222 apart) and positive ≥40 years (NCT04516746) B.1.427/B.1.429, hospitalization (Vaxzevria, 2 doses 81% NAAT result old and not 12 months after P.2, B.1.526 also called pregnant in UK and C.37 (>12 weeks (Pooled second dose Covishield when apart) efficacy (NCT04400838, manufactured by NCT04536051 4 67%) SII under license)) and NCT04516746) Johnson & Johnsonb Viral 1 dose 44,325 66% Symptomatic ≥18 years old 25 months B.1.351, P.1, 85.4% efficacy (Ad26.COV2-S)5,51 vector COVID-19 (NCT04505722) B.1.427/B.1.429, against and positive and 27 months P.2, B.1.526 and severe–critical RT–PCR test (NCT04614948) C.37 disease result after first dose occurring ≥28 days after vaccination Gamaleyab Viral 2 doses 19,866 92% Symptomatic ≥18 years old 6 months No variants No data (Sputnik V)6 vector (21 days COVID-19 after first dose have been available (June apart) and positive (NCT04656613 identified origi- 2021) RT–PCR test and nating from the result NCT04642339) trial locations from the trial start date to the present (June 2021) Bharat Biotechb Viral 2 doses 25,800 78% Symptomatic ≥18 years old 12 months after Phase III trial 100% efficacy (Covaxin)9 vector (28 days COVID-19 (2–18 years old: second dose began on against apart) and positive study ongoing) (NCT04641481); 16 November hospitalization RT–PCR test paediatric 2020 and is result at least cohort followed ongoing in India; 14 days after up for 9 months variants iden- second dose (NCT04918797) tified include B.1.617.2 and B.1.617.1 Sinovac Biotech Inacti- 2 doses 2,300 Multiple Symptomatic, ≥18 years old 12 months P.1 and P.2 51% efficacy (CoronaVac)7 vated (14 days (Chile); studies in virologically after first dose against virus apart; 13,000 different confirmed symptomatic 14 or (Turkey); countries: COVID-19 SARS-CoV-2 28 days 12,688 50.7% occurring infection; apart in (Brazil) (Brazil), from 2 weeks 100% efficacy Chile) 56.5% after the against severe (Chile), 65% second dose disease; (Indonesia), up to 1 year 100% efficacy 78% (Brazil) after the first against hospi- and 91% dose talization from (Turkey) 14 days after second dose NATURE REVIEWS | IMMUNOLOGY VOLUME 21 | OCTOBER 2021 | 627 0123456789();: PROGRESS Table 1 (cont.) | Reported COVID-19 vaccine efficacy data from phase III trials Vaccine Platform Clinical Total Efficacy End point Eligibility Duration of Circulating Results by manufacturer trial trial measure follow up for genotypes at severity (vaccine name)a regime size phase III trial location and time of trial Sinopharm Inacti- 2 doses 45,000 78% Occurrence ≥18 years old 12 months No variants 79% efficacy (BBIBP-CorV)7 vated (21 days of COVID-19 after first dose have been against virus apart) (NCT04510207) identified hospitalization originating from the trial locations during this time (June 2021) Novavaxb Protein 2 doses >15,000 89% Symptomatic ≥18 years old 24 months B.1.1.7 , B.1.351, 100% efficacy (NVX-CoV2373)8,46,65
Recommended publications
  • The Effectiveness of Non-Pharmaceutical Interventions In
    medRxiv preprint doi: https://doi.org/10.1101/2020.04.06.20054197; this version posted April 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . The effectiveness of non-pharmaceutical interventions in containing epidemics: a rapid review of the literature and quantitative assessment CHEATLEY Jane1, VUIK Sabine1, DEVAUX Marion1, SCARPETTA Stefano1, PEARSON Mark1, COLOMBO Francesca1, CECCHINI Michele1 1. Directorate for Employment, Labour and Social Affairs, Organization for Economic Co-operation and Development, Paris, France Corresponding author: CECCHINI Michele: [email protected] Abstract The number of confirmed COVID-19 cases has rapidly increased since discovery of the disease in December 2019. In the absence of medical countermeasures to stop the spread of the disease (i.e. vaccines), countries have responded by implementing a suite of non-pharmaceutical interventions (NPIs) to contain and mitigate COVID-19. Individual NPIs range in intensity (e.g. from lockdown to public health campaigns on personal hygiene), as does their impact on reducing disease transmission. This study uses a rapid review approach and investigates evidence from previous epidemic outbreaks to provide a quantitative assessment of the effectiveness of key NPIs used by countries to combat the COVID-19 pandemic. Results from the study are designed to help countries enhance their policy response as well as inform transition strategies by identifying which policies should be relaxed and which should not. Introduction In December 2019, Wuhan, located in the Hubei province of China, experienced an outbreak of pneumonia from a novel virus – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Chen et al., 2020[1]).
    [Show full text]
  • Molecular Analysis of SARS-Cov-2 Genetic Lineages in Jordan: Tracking the Introduction and Spread of COVID-19 UK Variant of Concern at a Country Level
    pathogens Article Molecular Analysis of SARS-CoV-2 Genetic Lineages in Jordan: Tracking the Introduction and Spread of COVID-19 UK Variant of Concern at a Country Level Malik Sallam 1,2,* and Azmi Mahafzah 1,2 1 Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, The University of Jordan, Amman 11942, Jordan; [email protected] 2 Department of Clinical Laboratories and Forensic Medicine, Jordan University Hospital, Amman 11942, Jordan * Correspondence: [email protected]; Tel.: +962-79-184-5186 Abstract: The rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is manifested by the emergence of an ever-growing pool of genetic lineages. The aim of this study was to analyze the genetic variability of SARS-CoV-2 in Jordan, with a special focus on the UK variant of concern. A total of 579 SARS-CoV-2 sequences collected in Jordan were subjected to maximum likelihood and Bayesian phylogenetic analysis. Genetic lineage assignment was undertaken using the Pango system. Amino acid substitutions were investigated using the Protein Variation Effect Analyzer (PROVEAN) tool. A total of 19 different SARS-CoV-2 genetic lineages were detected, with the most frequent being the first Jordan lineage (B.1.1.312), first detected in August 2020 (n = 424, 73.2%). This was followed by the second Jordan lineage (B.1.36.10), first detected in September 2020 (n = 62, 10.7%), and the UK variant of concern (B.1.1.7; n = 36, 6.2%). In the spike gene region, Citation: Sallam, M.; Mahafzah, A. the molecular signature for B.1.1.312 was the non-synonymous mutation A24432T resulting in a Molecular Analysis of SARS-CoV-2 deleterious amino acid substitution (Q957L), while the molecular signature for B.1.36.10 was the Genetic Lineages in Jordan: Tracking synonymous mutation C22444T.
    [Show full text]
  • REALM Research Briefing: Vaccines, Variants, and Venitlation
    Briefing: Vaccines, Variants, and Ventilation A Briefing on Recent Scientific Literature Focused on SARS-CoV-2 Vaccines and Variants, Plus the Effects of Ventilation on Virus Spread Dates of Search: 01 January 2021 through 05 July 2021 Published: 22 July 2021 This document synthesizes various studies and data; however, the scientific understanding regarding COVID-19 is continuously evolving. This material is being provided for informational purposes only, and readers are encouraged to review federal, state, tribal, territorial, and local guidance. The authors, sponsors, and researchers are not liable for any damages resulting from use, misuse, or reliance upon this information, or any errors or omissions herein. INTRODUCTION Purpose of This Briefing • Access to the latest scientific research is critical as libraries, archives, and museums (LAMs) work to sustain modified operations during the continuing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. • As an emerging event, the SARS-CoV-2 pandemic continually presents new challenges and scientific questions. At present, SARS-CoV-2 vaccines and variants in the US are two critical areas of focus. The effects of ventilation-based interventions on the spread of SARS-CoV-2 are also an interest area for LAMs. This briefing provides key information and results from the latest scientific literature to help inform LAMs making decisions related to these topics. How to Use This Briefing: This briefing is intended to provide timely information about SARS-CoV-2 vaccines, variants, and ventilation to LAMs and their stakeholders. Due to the evolving nature of scientific research on these topics, the information provided here is not intended to be comprehensive or final.
    [Show full text]
  • COVID-19 Vaccines: Update on Allergic Reactions, Contraindications, and Precautions
    Centers for Disease Control and Prevention Center for Preparedness and Response COVID-19 Vaccines: Update on Allergic Reactions, Contraindications, and Precautions Clinician Outreach and Communication Activity (COCA) Webinar Wednesday, December 30, 2020 Continuing Education Continuing education will not be offered for this COCA Call. To Ask a Question ▪ All participants joining us today are in listen-only mode. ▪ Using the Webinar System – Click the “Q&A” button. – Type your question in the “Q&A” box. – Submit your question. ▪ The video recording of this COCA Call will be posted at https://emergency.cdc.gov/coca/calls/2020/callinfo_123020.asp and available to view on-demand a few hours after the call ends. ▪ If you are a patient, please refer your questions to your healthcare provider. ▪ For media questions, please contact CDC Media Relations at 404-639-3286, or send an email to [email protected]. Centers for Disease Control and Prevention Center for Preparedness and Response Today’s First Presenter Tom Shimabukuro, MD, MPH, MBA CAPT, U.S. Public Health Service Vaccine Safety Team Lead COVID-19 Response Centers for Disease Control and Prevention Centers for Disease Control and Prevention Center for Preparedness and Response Today’s Second Presenter Sarah Mbaeyi, MD, MPH CDR, U.S. Public Health Service Clinical Guidelines Team COVID-19 Response Centers for Disease Control and Prevention National Center for Immunization & Respiratory Diseases Anaphylaxis following mRNA COVID-19 vaccination Tom Shimabukuro, MD, MPH, MBA CDC COVID-19 Vaccine
    [Show full text]
  • COVID-19 Vaccination Programme: Information for Healthcare Practitioners
    COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1.
    [Show full text]
  • Considerations for Causality Assessment of Neurological And
    Occasional essay J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2021-326924 on 6 August 2021. Downloaded from Considerations for causality assessment of neurological and neuropsychiatric complications of SARS- CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder Matt Butler ,1 Arina Tamborska,2,3 Greta K Wood,2,3 Mark Ellul,4 Rhys H Thomas,5,6 Ian Galea ,7 Sarah Pett,8 Bhagteshwar Singh,3 Tom Solomon,4 Thomas Arthur Pollak,9 Benedict D Michael,2,3 Timothy R Nicholson10 For numbered affiliations see INTRODUCTION More severe potential adverse effects in the open- end of article. The scientific community rapidly responded to label phase of vaccine roll- outs are being collected the COVID-19 pandemic by developing novel through national surveillance systems. In the USA, Correspondence to SARS- CoV-2 vaccines (table 1). As of early June Dr Timothy R Nicholson, King’s roughly 372 adverse events have been reported per College London, London WC2R 2021, an estimated 2 billion doses have been million doses, which is a lower rate than expected 1 2LS, UK; timothy. nicholson@ administered worldwide. Neurological adverse based on the clinical trials.6 kcl. ac. uk events following immunisation (AEFI), such as In the UK, adverse events are reported via the cerebral venous sinus thrombosis and demyelin- MB and AT are joint first Coronavirus Yellow Card reporting website. As of ating episodes, have been reported. In some coun- authors. early June 2021, approximately 250 000 Yellow tries, these have led to the temporary halting of BDM and TRN are joint senior Cards have been submitted, equating to around authors.
    [Show full text]
  • COVID-19 Weekly Epidemiological Update
    COVID-19 Weekly Epidemiological Update Edition 45, published 22 June 2021 In this edition: • Global overview • Special focus: Update on SARS-CoV-2 Variants of Interest and Variants of Concern • Special focus: Global Consultation on SARS-CoV-2 Variants of Concern and their Impact on Public Health Interventions • WHO regional overviews • Key weekly updates Global overview Data as of 20 June 2021 Global numbers of cases and deaths continued to decrease over the past week (14-20 June 2021) with over 2.5 million new weekly cases and over 64 000 deaths, a 6% and a 12% decrease respectively, compared to the previous week (Figure 1). While the number of cases reported globally now exceeds 177 million, last week saw the lowest weekly case incidence since February 2021. This week, the Americas and Western Pacific Regions reported numbers of new weekly cases similar to the previous week, while the South-East Asia and the European Regions reported a decline in the number of new cases. The African Region recorded a marked increase in the number of weekly cases as compared to the previous week (Table 1). Globally, mortality remains high with more than 9000 deaths reported each day over the past week, however, the number of new deaths reported in the past week decreased across all Regions except for the Eastern Mediterranean and the African Regions. Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 20 June 2021** 6 000 000 120 000 Americas South-East Asia 5 000 000 100 000 Europe Eastern Mediterranean 4 000 000 Africa
    [Show full text]
  • Effectiveness of COVID-19 Vaccines Against Variants of Concern, Canada
    medRxiv preprint doi: https://doi.org/10.1101/2021.06.28.21259420; this version posted July 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Effectiveness of COVID-19 vaccines against variants of concern, Canada Authors: Sharifa Nasreen PhD1, Siyi He MSc1, Hannah Chung MPH1, Kevin A. Brown PhD1,2,3, Jonathan B. Gubbay MD MSc3, Sarah A. Buchan PhD1,2,3,4, Sarah E. Wilson MD MSc1,2,3,4, Maria E. Sundaram PhD1,2, Deshayne B. Fell PhD1,5,6, Branson Chen MSc1, Andrew Calzavara MSc1, Peter C. Austin PhD1,7, Kevin L. Schwartz MD MSc1,2,3, Mina Tadrous PharmD PhD1,8, Kumanan Wilson MD MSc9, and Jeffrey C. Kwong MD MSc1,2,3,4,10,11 on behalf of the Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators Affiliations: 1 ICES, Toronto, ON 2 Dalla Lana School of Public Health, University of Toronto, Toronto, ON 3 Public Health Ontario, ON 4 Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, ON 5 School of Epidemiology and Public Health, University of Ottawa, ON 6 Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON 7 Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON 8 Women’s College Hospital, Toronto, ON 9 Department of Medicine, University of Ottawa, Ottawa and Bruyere Hospital Research Institutes, Ottawa, ON 10 Department of Family and Community Medicine, University of Toronto, Toronto, ON 11 University Health Network, Toronto, ON Corresponding author: 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • Electronic Support for Public Health–Vaccine Adverse Event Reporting System (ESP:VAERS)
    Grant Final Report Grant ID: R18 HS 017045 Electronic Support for Public Health–Vaccine Adverse Event Reporting System (ESP:VAERS) Inclusive dates: 12/01/07 - 09/30/10 Principal Investigator: Lazarus, Ross, MBBS, MPH, MMed, GDCompSci Team members: Michael Klompas, MD, MPH Performing Organization: Harvard Pilgrim Health Care, Inc. Project Officer: Steve Bernstein Submitted to: The Agency for Healthcare Research and Quality (AHRQ) U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Abstract Purpose: To develop and disseminate HIT evidence and evidence-based tools to improve healthcare decision making through the use of integrated data and knowledge management. Scope: To create a generalizable system to facilitate detection and clinician reporting of vaccine adverse events, in order to improve the safety of national vaccination programs. Methods: Electronic medical records available from all ambulatory care encounters in a large multi-specialty practice were used. Every patient receiving a vaccine was automatically identified, and for the next 30 days, their health care diagnostic codes, laboratory tests, and medication prescriptions were evaluated for values suggestive of an adverse event. Results: Restructuring at CDC and consequent delays in terms of decision making have made it challenging despite best efforts to move forward with discussions regarding the evaluation of ESP:VAERS performance in a randomized trial and comparison of ESP:VAERS performance to existing VAERS and Vaccine Safety Datalink data. However, Preliminary data were collected and analyzed and this initiative has been presented at a number of national symposia. Key Words: electronic health records, vaccinations, adverse event reporting The authors of this report are responsible for its content.
    [Show full text]
  • COVID-19 Vaccineadmin VAERS
    Reporting a Suspected Vaccine Adverse Event Indian Health Service, National Pharmacy & Therapeutics Committee CAPT Matthew Clark, MD, FAAP, FACP, Chair CAPT Ryan Schupbach, PharmD, BCPS, CACP, Vice Chair CAPT Christopher Lamer, PharmD, MHS, BCPS, CDE, Director of Pharmacovigilance October 2020 Potential New Vaccine for COVID-19 • Operation Warp Speed (OWS) • Collaboration between the Federal Government and biopharmaceutical companies to develop medications, diagnostic tests, and vaccines. • Shortened timelines but safety and efficacy are the primary focus. • Vaccines must be at least 50% effective for FDA EUA or approval. • Vaccines must be safe, and benefits of immunization must outweigh any risks of adverse events. • Continued need for influenza immunization • Continued need for scheduled immunizations https://www.hhs.gov/coronavirus/explaining-operation-warp-speed/index.html 2 Vaccine Safety: Common Adverse Events Vaccines are considered to be safe and effective with most common adverse events being mild and are signs that the body is developing immunity: • Pain, swelling, or redness where the shot was given • Mild fever • Chills • Feeling tired • Headache • Muscle and joint aches https://www.vaccines.gov/basics/safety/side_effects 3 Vaccine Safety: Serious Adverse Events More serious side effects are rare but can occur. Some examples are: • Anaphylaxis (0.65 cases/1 million vaccinations) • Thrombocytopenia from Rubella vaccine (1 case/40,000 vaccinations) • Orchitis from Mumps vaccine (0.3 cases/1 million vaccinations) • Intussusception from Rotavirus vaccine (1 case/100,000 vaccinations) • Guillain-Barre from flu vaccine (1 case/1.25 million vaccinations; association is stronger with flu infection than the vaccine) Spencer JP, Trondsen Pawlowski RH, Thomas S. Vaccine Adverse Events: Separating Myth from Reality.
    [Show full text]
  • Non-Pharmaceutical Interventions and Mortality in U.S. Cities During the Great Influenza Pandemic, 1918-1919*
    Non-Pharmaceutical Interventions and Mortality in U.S. Cities during the Great Influenza Pandemic, 1918-1919* Robert J. Barro Harvard University August 2020 Abstract A key issue for the ongoing COVID-19 pandemic is whether non-pharmaceutical public-health interventions (NPIs) retard death rates. Good information about these effects comes from flu- related excess deaths in large U.S. cities during the second wave of the Great Influenza Pandemic, September 1918-February 1919. NPIs, as measured by an extension of Markel, et al. (2007), are in three categories: school closings, prohibitions on public gatherings, and quarantine/isolation. Although an increase in NPIs flattened the curve in the sense of reducing the ratio of peak to average death rates, the estimated effect on overall deaths is small and statistically insignificant. One possibility is that the NPIs were not more successful in curtailing overall mortality because the average duration of each type of NPI was only around one month. Another possibility is that NPIs mainly delay deaths rather than eliminating them. *I have benefited from comments by Martin Cetron, Sergio Correia, Ed Glaeser, Claudia Goldin, Chris Meissner, and Jim Stock, and from research assistance by Emily Malpass. 1 The mortality experienced during the Great Influenza Pandemic of 1918-1920 likely provides the best historical information on the plausible upper found for outcomes under the ongoing coronavirus (COVID-19) pandemic. Barro, Ursúa, and Weng (2020) compiled and discussed the cross-country data on flu-related deaths during the Great Influenza Pandemic. Based on information for 48 countries, that study found that the Pandemic killed around 40 million people, 2.1 percent of the world’s population.
    [Show full text]
  • Oral Abstracts
    THE IMPACT OF VACCINES WORLDWIDE AND THE CHALLENGES TO ACHIEVE UNIVERSAL IMMUNIZATION Jean-Marie Okwo-Bele, Former Director of the WHO Immunization and Vaccines Department Independent Consultant, Switzerland [email protected] Key Words: immunization programme, vaccine impact, data quality, ownership, life-course This presentation will provide an overview of the current status of the global immunization programme using available published and non-published data from WHO Member States and review the pathways to alleviate the main barriers towards achieving universal immunization during this era of the UN Sustainable Development Goals. In 1974, the establishment of the WHO Expanded Programme on Immunization marked a turning point in the large-scale use of vaccines. Today, more children than ever are being reached with immunization; polio is on the verge of being eradicated, the WHO model list of vaccines now includes twenty-two vaccines for all ages that countries can choose from. The health impact is evident with the continued decline of under-five mortality due to vaccine-preventable diseases from roughly 4million deaths in 2000 to less than 2million deaths in 2015. Overall, WHO estimates that vaccines prevent 2-3 million deaths each year. The broader benefits of vaccines are also well documented. In 2011, the Global Vaccine Action Plan for this Decade of Vaccines was produced with the ambitions to close the equity gap in vaccine coverage and to unleash the vaccines vast potentials. An independent assessment of the GVAP implementation was carried out by the WHO Strategic Advisory Group of Experts (SAGE) on Immunization which expressed strong concerns that most countries were off track to achieving their immunization goals.
    [Show full text]